Journal
AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 116, Issue 1, Pages 45-56Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.14309/ajg.0000000000000844
Keywords
-
Categories
Ask authors/readers for more resources
Biological therapy targeting tumor necrosis factor-alpha has become crucial in treating patients with inflammatory bowel disease, but high costs limit accessibility. Biosimilars offer the potential to reduce expenditures and increase availability, providing more options for patients.
Over the past 2 decades, biological therapy with monoclonal antibodies targeting tumor necrosis factor-alpha has become a cornerstone of treatment of patients with inflammatory bowel disease. Although clinically effective, the biological therapies remain expensive, and their availability and utilization have been at times limited due to their high costs. Biosimilars are biological products similar to but not identical to the original biological agent or reference biologic, also called originator biologic. It is hoped that the use of biosimilars might enable these agents to become more available and, thus, decrease further expenditures related to the use of the original reference agents such as infliximab and adalimumab. In this study, we review the currently available evidence and shortcomings of these data supporting the use of biosimilars for the treatment of patients with inflammatory bowel disease, including their efficacy and safety as related to initiating therapy with biosimilar agents or switching between reference and biosimilar biologic agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available